Managing Type 2 Diabetes: Balancing HbA_1c and Body Weight

References

• . Cowie CC, Rust KF, Ford ES, . Full accounting of diabetes and pre-diabetes in the U.S. population in 1988–1994 and 2005–2006. Diabetes Care. 2009;32(2):287–294
   PubMed Web of Science ®Google Scholar
• . Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. JAMA. 2010;303(3):235–241
   PubMed Web of Science ®Google Scholar
• . Mokdad AH, Ford ES, Bowman BA, . Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289(1):76–79
   PubMed Web of Science ®Google Scholar
• . Eeg-Olofsson K, Cederholm J, Nilsson PM, . Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia. 2009;52(1):65–73
   PubMed Web of Science ®Google Scholar
• . Yki-Jarvinen H, Ryysy L, Kauppila M, . Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metabolism. 1997;82(12):4037–4043
   PubMed Web of Science ®Google Scholar
• . Tankova T, Dakovska G, Lazarova M, Dakovska L, Kirilov G, Koev D. Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects. Acta Diabetol. 2004;41(4):146–153
   PubMed Web of Science ®Google Scholar
• . Smith BR, Hinojosa MW, Reavis KM, Nguyen NT. Remission of diabetes after laparoscopic gastric bypass. Am Surg. 2008;74(10):948–952
   PubMed Web of Science ®Google Scholar
• . Amaryl [package insert]. Bridgewater, NJ: sanofi-aventis; 2009
   Google Scholar
• . Glucotrol [package insert]. New York, NY: Pfizer Inc; 2006
   Google Scholar
• . Glynase [package insert]. New York, NY: Pfizer Inc; 2006
   Google Scholar
• . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS). Lancet. 1998;352(9131):837–853
   PubMed Web of Science ®Google Scholar
• . Coniff RF, Shapiro JA, Seaton TB, Bray GA. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med. 1995;98(5):443–451
   PubMed Web of Science ®Google Scholar
• . Garber AJ, Larsen J, Schneider SH, Piper BA, Henry D. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab. 2002;4(3):201–208
   PubMed Web of Science ®Google Scholar
• . Scott R, Wu M, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract. 2007;61(1):171–180
   PubMed Web of Science ®Google Scholar
• . Goldstein BJ, Pans M, Rubin CJ. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea. Clin Ther. 2003;25(3):890–903
   PubMed Web of Science ®Google Scholar
• . Tan M, Johns D, Gonzalez Galvez G, . Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial. Clin Ther. 2004;26(5):680–693
   PubMed Web of Science ®Google Scholar
• . Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest. 2000;106(4): 467–472
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care. 2007;30(2):217–223
   PubMed Web of Science ®Google Scholar
• . Kahn SE, Haffner SM, Heise MA, . Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427–2443
   PubMed Web of Science ®Google Scholar
• . Dormandy JA, Charbonnel B, Eckland DJ, ; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–1289
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Kim SW, Baron MA, . Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9(2):175–185
   PubMed Web of Science ®Google Scholar
• . Miyazaki Y, Mahankali A, Matsuda M, . Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002;87(6):2784–2791
   PubMed Web of Science ®Google Scholar
• . Mori Y, Murakawa Y, Okada K, . Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care. 1999;22(6):908–912
   PubMed Web of Science ®Google Scholar
• . Rizos CV, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother. 2008;9(7):1087–1108
   PubMed Web of Science ®Google Scholar
• . Starlix [package insert]. East Hanover, NJ: Novartis; 2008
   Google Scholar
• . Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care. 2000;23(11):1660–1665
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Shen SG, Gatlin MR, Foley JE. Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes. Diabetes Care. 2002;25(9):1529–1533
   PubMed Web of Science ®Google Scholar
• . Prandin [package insert]. Princeton, NJ: Novo Nordisk; 2006
   Google Scholar
• . Raskin P, McGill J, Saad MF, ; Repaglinide/Rosiglitazone Study Group. Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone. Diabet Med. 2004;21(4):329–335
   PubMed Web of Science ®Google Scholar
• . Glucophage [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2009
   Google Scholar
• . DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995;333(9):541–549
   PubMed Web of Science ®Google Scholar
• . Stewart MW, Cirkel DT, Furuseth K, . Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetes. Diabet Med. 2006;23(10):1069–1078
   PubMed Web of Science ®Google Scholar
• . Aviles-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999;131(3):182–188
   PubMed Web of Science ®Google Scholar
• . Chaudhuri A, Tomar R, Mohanty P, . The combination of insulin and metformin in treatment of non-insulin-dependent diabetes mellitus. Endocr Pract. 1998;4(5):259–267
   PubMedGoogle Scholar
• . Precose [package insert]. Wayne, NJ: Bayer Pharmaceuticals; 2008
   Google Scholar
• . Pan C, Yang W, Barona JP, . Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med. 2008;25:435–441
   PubMed Web of Science ®Google Scholar
• . Chiasson JL, Naditch L; Miglitol Canadian University Investigator Group. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. Diabetes Care. 2001;24(6):989–994
   PubMed Web of Science ®Google Scholar
• . Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals; 2008
   Google Scholar
• . Victoza [package insert]. Princeton, NJ: Novo Nordisk; 2010
   Google Scholar
• . Moretto TJ, Milton DR, Ridge TD, . Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008;30(8):1448–1460
   PubMed Web of Science ®Google Scholar
• . Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract. 2007;13(5):444–450
   PubMedGoogle Scholar
• . Drucker DJ, Buse JB, Taylor K, . Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240–1250
   PubMed Web of Science ®Google Scholar
• . Buse JB, Drucker DJ, Taylor KL, ; DURATION-1 Study Group. DURATION-1: Exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks [published online ahead of print March 9, 2010]. Diabetes Care. DOI: 10.2337/dc09-1914
   Google Scholar
• . Garber A, Henry R, Ratner R, . Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473–481
   PubMed Web of Science ®Google Scholar
• . Buse JB, Rosenstock J, Sesti G, . Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39–47
   PubMed Web of Science ®Google Scholar
• . Symlin [package insert]. San Diego, CA: Amylin Pharmaceuticals; 2008
   Google Scholar
• . Hollander PA, Levy P, Fineman MS, . Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003;26(3):784–790
   PubMed Web of Science ®Google Scholar
• . Karl D, Philis-Tsimikas A, Darsow T, . Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight. Diabetes Technol Ther. 2007;9(2):191–199
   PubMed Web of Science ®Google Scholar
• . Januvia [package insert]. Whitehouse Station, NJ: Merck and Co; 2007
   Google Scholar
• . Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29(12):2632–2637
   PubMed Web of Science ®Google Scholar
• . Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 03 Study Group.Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30(8):1979–1987
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin. 2009;25(10):2401–2411
   PubMed Web of Science ®Google Scholar
• . Kelley DE, Bray GA, Pi-Sunyer FX, . Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care. 2002;25(6):1033–1041
   PubMed Web of Science ®Google Scholar
• . Miles JM, Leiter L, Hollander P, . Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care. 2002;25(7):1123–1128
   PubMed Web of Science ®Google Scholar
• . McNulty SJ, Ur E, Williams G; Multicenter Sibutramine Study Group.A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care. 2003;26(1):125–131
   PubMed Web of Science ®Google Scholar
• . Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. Diabetes Nutr Metab. 2004;17(4):222–229
   PubMedGoogle Scholar
• . Brunton S. Beyond glycemic control: treating the entire type 2 diabetes disorder. Postgrad Med. 2009;121(5):68–81
   PubMed Web of Science ®Google Scholar
• . Blevins T. Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes. Postgrad Med. 2010;122(1):172–183
   PubMed Web of Science ®Google Scholar